Core Viewpoint - The company, Kaili Medical, reported a strong performance in Q1 2025, with a focus on high-end and specialized product development, which is expected to drive continuous revenue growth throughout the year [1][4]. Financial Performance - In Q1 2025, Kaili Medical achieved a revenue of 430 million yuan and a net profit attributable to shareholders of 8.07 million yuan, with a non-recurring net profit of 5.9981 million yuan [1]. - The company’s R&D investment in Q1 2025 was 126 million yuan, reflecting a year-on-year increase of 23.7% [2]. Product Development and Innovation - Kaili Medical launched several high-end products, including the 4K iEndo smart endoscope platform, which has received NMPA registration and is now in the market promotion phase [2]. - The iEndo platform features an independent GPU module that enhances image processing and AI computing capabilities, providing clearer and more precise imaging for clinical diagnosis [2]. - New products in the digestive and respiratory endoscope categories include advanced gastric and intestinal endoscopes, designed with ergonomic improvements to enhance usability and reduce fatigue for physicians [3]. Market Trends and Opportunities - The domestic medical equipment market is expected to grow by over 20% compared to last year, driven by government policies supporting equipment updates and procurement [1]. - The company is positioned to benefit from the increasing market share in ultrasound and endoscopy, alongside the maturation of its minimally invasive surgery and cardiovascular intervention product lines [4]. - Kaili Medical aims to establish a comprehensive multi-product line development strategy, integrating diagnostics and treatment across various specialties [4].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司 2025 年一季度报告于 2025 年 4 月 26 日在中国证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com. cn/）上披露，请投资者注意查阅。 特此公告。 深圳开立生物医疗科技股份有限公司董事会 2025 年 4 月 25 日 证券代码：300633 证券简称：开立医疗 公告编号：2025-023 深圳开立生物医疗科技股份有限公司 2025 年第一季度报告披露提示性公告 ...

第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 4 月 24 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第四届监事会第七次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼会 议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 证券代码：300633 证券简称：开立医疗 公告编号：2025-025 深圳开立生物医疗科技股份有限公司 经审核，监事会认为：公司《2025 年一季度报告》的编制和审议程序符合法 律、法规、公司章程和公司内部管理制度的规定，公司《2025 年一季度报告》的 内容和格式符合中国证监会和深圳证券交易所的各项规定，所披露的信息真实、 准确、完整地反映了公司的实际经营情况，不存在虚假记载、误导性陈述或者重 大遗漏。 特此公告。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 三、备查文件 1、第四届监事会第七次会议 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：300633 证券简称：开立医疗 公告编号：2025-024 深圳开立生物医疗科技股份有限公司 第四届董事会第八次会议决议公告 三、备查文件 1、第四届董事会第八次会议决议。 2025 年 4 月 24 日，深圳开立生物医疗科技股份有限公司（以下简称"公司"） 第四届董事会第八次会议以现场和通讯表决相结合的方式在深圳市光明区光电 北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2025 年 4 月 18 日以 电话、电子邮件等方式通知全体董事。 特此公告。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于公司 2025 年第一季度报告的议案》 董事会认为：公司《2025 年一季度报告》的内容真实、准确、完整地反映了 公司 2025 年一季度经营的实际情况，不存在任何 ...

Financial Performance - The company reported a significant decline in basic earnings per share, dropping to 0.0187 yuan in Q1 2025 from 0.2326 yuan in Q1 2024, representing a decrease of 91.96% [1] - Net profit for Q1 2025 was 0.08 billion yuan, down 92% from 1 billion yuan in Q1 2024 [1] - Revenue decreased to 4.3 billion yuan in Q1 2025, a decline of 10.23% compared to 4.79 billion yuan in Q1 2024 [1] - The return on equity fell to 0.26% in Q1 2025 from 3.13% in Q1 2024, marking a decrease of 91.69% [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 98.7644 million shares, accounting for 22.83% of the circulating shares, with a decrease of 2.2972 million shares compared to the previous period [1] - Major shareholders include Chen Zhiqiang and Wu Kunxiang, each holding 23.9313 million shares, representing 5.53% of the total share capital, with no change in their holdings [2] - The Hong Kong Central Clearing Limited reduced its holdings by 2.1367 million shares, now holding 5.6405 million shares, which is 1.30% of the total share capital [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

Financial Performance - The company's revenue for Q1 2025 was ¥430,012,001.93, a decrease of 10.29% compared to ¥479,333,865.45 in the same period last year[4] - Net profit attributable to shareholders was ¥8,074,620.52, down 91.94% from ¥100,190,827.63 year-on-year[4] - Total operating revenue for the current period is ¥430,012,001.93, a decrease of 10.3% from ¥479,333,865.45 in the previous period[17] - Net profit for the current period is ¥8,074,620.52, down 91.9% from ¥100,190,827.63 in the previous period[18] - Basic earnings per share decreased to ¥0.0187 from ¥0.2326, reflecting a significant decline in profitability[18] - The weighted average return on equity was 0.26%, down from 3.13% in the same period last year, indicating a significant decline in profitability[4] Cash Flow - The net cash flow from operating activities was -¥284,864,541.91, representing a decline of 899.07% compared to -¥28,513,064.73 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥284,864,541.91, compared to a smaller outflow of ¥28,513,064.73 in the previous period[20] - The company reported a cash inflow from investment activities of ¥499,535,533.27, a significant increase compared to ¥17,769.69 in the previous period[20] - Net cash flow from investment activities was 320,146,424.73, compared to a negative cash flow of -72,622,271.05 in the previous period[21] - Net cash flow from financing activities was -154,416,991.98, a significant decrease compared to a positive cash flow of 226,745,799.91 in the previous period[21] - Cash inflow from financing activities was 21,167,720.37, down from 259,332,185.06 in the previous period[21] - The net increase in cash and cash equivalents was -118,050,845.31, contrasting with an increase of 126,702,284.38 in the previous period[21] - Cash paid for debt repayment was 168,918,309.64, indicating a significant cash outflow in financing activities[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,995,840,487.69, a decrease of 7.35% from ¥4,312,997,155.23 at the end of the previous year[5] - Total current assets decreased from CNY 2,974,995,087.77 to CNY 2,645,522,089.15, a reduction of approximately 11%[14] - Total liabilities decreased to ¥871,322,477.26 from ¥1,204,774,675.82, reflecting a reduction in financial obligations[16] - Total equity attributable to shareholders increased to ¥3,124,518,010.43 from ¥3,108,222,479.41, showing a slight growth in shareholder value[16] Investments and R&D - R&D expenses increased by 23.70% to ¥125,724,100.00, reflecting the company's commitment to new product development[9] - Research and development expenses increased to ¥125,724,109.43, up 23.6% from ¥101,637,595.01 in the previous period, indicating a focus on innovation[17] - The company reported a significant increase in investment income, which rose by 150.19% to ¥979,200.00, attributed to higher returns from financial products[9] - The cash flow from investment activities showed a net increase of 540.84%, amounting to ¥320,146,400.00, due to more redemptions of financial products than purchases[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,519[10] - The top two shareholders, Chen Zhiqiang and Wu Kunxiang, each hold 22.12% of shares, totaling 95,725,200 shares, both of which are pledged[10] Other Information - The company received government subsidies amounting to ¥1,266,210.55, contributing positively to its financial performance[6] - The company has no preferred shareholders or changes in restricted shares during the reporting period[12] - The company did not undergo an audit for the first quarter report[22] - The new accounting standards will be implemented starting from 2025[22]

长城证券股份有限公司 关于深圳开立生物医疗科技股份有限公司 2024 年度持续督导跟踪报告 | 项 目 | 工作内容 | | --- | --- | | 1．公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 | | | 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3．募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 次 1 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4．公司治理督导情况 | | | （1）列席公司股东大会次数 | 次 0 | | （2）列席公司董事会次数 | 次 0 | | （3）列席公司监事会次数 | 0 次 | | 项 目 | 工作内容 | | --- | --- | | 5．现场检查情况 | | ...

长城证券股份有限公司 关于深圳开立生物医疗科技股份有限公司 向特定对象发行股票之保荐工作总结报告书 经中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意 深圳开立生物医疗科技股份有限公司向特定对象发行股票注册的批复》（证监许 可[2021]668 号）核准，深圳开立生物医疗科技股份有限公司（以下简称"开立 医疗"、"上市公司"、"发行人"或"公司"）向特定对象发行人民币普通股 （A 股）27,851,745 股，发行价格为 27.79 元/股，募集资金总额为人民币 773,999,993.55 元，扣除发行费用（不含税）合计人民币 4,944,026.20 元后，募 集资金净额为人民币 769,055,967.35 元。天健会计师事务所（特殊普通合伙）对 以上募集资金到账情况出具了《深圳开立生物医疗科技股份有限公司验资报告》 （天健验[2021]3-78 号）。 长城证券股份有限公司（以下简称"保荐机构"或"长城证券"）作为开立 医疗本次向特定对象发行股票的保荐机构，自公司向特定对象发行股票发行完成 之日至 2024 年 12 月 31 日（以下简称"本持续督导期间"）履行持续督导责任。 目前， ...

长城证券股份有限公司关于 深圳开立生物医疗科技股份有限公司 2024 年度持续督导现场检查报告 | 保荐人名称：长城证券股份有限公司 被保荐公司简称：开立医疗 | | --- | | 保荐代表人姓名：郭小元 联系电话：010-88366060 | | 保荐代表人姓名：杨虎 联系电话：0755-83516072 | | 现场检查人员姓名：杨虎 | | 年度 现场检查对应期间：2024 | | 现场检查时间：2025 年 月 日-2025 年 月 日 4 17 4 18 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：1.查阅公司章程和公司治理相关制度；2.查阅公司三会文件及相关信息披 | | 露文件，核查其执行情况；3.核查董监高人员变动及相关决策文件、公告文件；4.核查控 | | 股股东、实际控制人是否发生变动情况及其对外投资情况 | | 1.公司章程和公司治理制度是否完备、合规 √ | | 2.公司章程和三会规则是否得到有效执行 √ | | 3.三会会议记录是否完整，时间、地点、出席人员及会议内 √ | | 容等要件是否齐备，会议资料是否保存完整 | | ...

长城证券股份有限公司关于 深圳开立生物医疗科技股份有限公司持续督导期 2024 年度培训情况的报告 深圳证券交易所： 长城证券股份有限公司（以下简称"长城证券"、"保荐机构"）作为深圳开 立生物医疗科技股份有限公司（以下简称"开立医疗"、"公司"） 2020 年度向特 定对象发行 A 股股票（以下简称"本次发行"）的保荐机构，根据《深圳证券交 易所创业板股票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》和《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等相关法律法规和规范性文件的要求，结合开立 医疗的实际情况，认真履行保荐机构应尽的职责，对开立医疗实际控制人、董事、 监事、高级管理人员等相关人员进行了持续督导培训，培训内容严格按照中国证 券监督管理委员会及深圳证券交易所创业板有关持续督导的最新要求进行。现将 相关情况报告如下： 一、培训时间 2025 年 4 月 17 日 二、培训地点 四、培训对象 开立医疗控股股东及实际控制人、董事、监事、高级管理人员等相关人员。 五、培训内容 本次培训内容包括：2024 年度创业板上市公司处罚案例 ...